{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-182137","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.869991+00:00","generated_at":"2026-05-15T03:54:12.242666+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Erasca reports positive Phase 1 data for pan-RAS glue ERAS-0015: 62% uORR in 2L+ KRAS G12X NSCLC","bullets":["62% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X NSCLC at PADs 16-32 mg QD (N=37), exceeding RMC-6236 by 24 ppt.","40% unconfirmed ORR at 14 weeks in 2L KRAS G12X PDAC at PADs (N=20), exceeding comparator by 11 ppt.","100% of patients (14/14) at PADs showed ≥75% reduction in KRAS G12X ctDNA; 5 showed 100% reduction.","No DLTs; well-tolerated with no discontinuations due to TRAEs; one Grade 5 pneumonitis event after withdrawal of care.","Monotherapy RDEs set at 24 and 32 mg QD; expansion and combo dose escalation initiated ahead of guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-182137","json":"https://secwatch.observer/filing/0001193125-26-182137.json","markdown":"https://secwatch.observer/filing/0001193125-26-182137.md","text":"https://secwatch.observer/filing/0001193125-26-182137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/0001193125-26-182137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/d126999d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:54:12.242666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}